Michael Brotherton

Michael began his career in endocrinology research before transitioning to a healthcare investment bank where he focused on building out specific coverage in the neuropsychiatry / psychedelics sector.  He currently works to connect companies in the space to strategic capital.   Michael is passionate about human optimization, the intersection of psychedelics and longevity, and psychedelics in end of life care.  Michael holds Series 63, Series 7 and Series 79 licenses.